A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency
An Open-label, Multicentre Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of AEB1102 in Patients With Arginase 1 Deficiency
The purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
California
-
Stanford, California, Estados Unidos, 94305
- Stanford University School of Medicine
-
-
Florida
-
Gainsville, Florida, Estados Unidos, 32610
- University of Florida
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- UTSW
-
-
-
-
-
Porto, Portugal
- Centro Hospitalar S. Joao
-
-
-
-
-
London, Reino Unido
- Great Ormond Street Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Complete treatment in Study CAEB1102-101A without experiencing any clinically significant adverse event or other unmanageable drug toxicity that would preclude continued dosing
- Confirmation by the Investigator and the Sponsor determine that it is acceptable for the patient to continue dosing with AEB1102
- If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
- If sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
- Patient or legal guardian is able and willing to provide written informed consent and where required assent, and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification), prior to any screening procedures
Exclusion Criteria:
1. Clinically significant concurrent disease, serious intercurrent illness, or other extenuating circumstances
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: pegzilarginase (AEB1102)
Each patient may receive pegzilarginase administered IV or SC for up to 4 years. |
modified human arginase I
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Number of Participants With Treatment-related Adverse Events
Prazo: From start of study up to 262 weeks
|
From start of study up to 262 weeks
|
|
Number of Participants With Anti-pegzilarginase and Anti-PEG Antibodies
Prazo: From start of study up to 262 weeks
|
From start of study up to 262 weeks
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Plasma Arginine Levels
Prazo: From start of study up to 240 weeks
|
Change in plasma arginine concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (Argininic Acid)
Prazo: From start of study up to 240 weeks
|
Change in plasma argininic acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (Guanidinoacetic Acid)
Prazo: From start of study up to 240 weeks
|
Change in plasma guanidinoacetic acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (α-keto-δ-guanidinovaleric Acid)
Prazo: From start of study up to 240 weeks
|
Change in plasma α-keto-δ-guanidinovaleric acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (α-N-acetylarginine)
Prazo: From start of study up to 240 weeks
|
Change in plasma α-N-acetylarginine concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Six-Minute Walk Test (6MWT)
Prazo: From start of study up to 262 weeks
|
Change in 6MWT distance from study Baseline |
From start of study up to 262 weeks
|
|
Gross Motor Function Measure (GMFM) Part D
Prazo: From start of study up to 262 weeks
|
Change from study Baseline. The GMFM-D evaluates the patient's ability to stand via assessment of 13 activities, each of which is scored on a scale of 0 to 3, with a scale range of 0-39 points. An increase in GMFM-D score indicates improvement in standing. |
From start of study up to 262 weeks
|
|
Gross Motor Function Measure (GMFM) Part E
Prazo: From start of study up to 262 weeks
|
Change from study Baseline. The GMFM-E evaluates a subject's ability to walk, run, and jump via assessment of 24 activities, each of which is scored on a scale of 0 to 3, , with a scale range of 0-72. A higher GMFM-E score indicates greater ability, with increasing scores indicating improvement in walking, running, and jumping. |
From start of study up to 262 weeks
|
|
Modified Ashworth Scale (MAS)
Prazo: From start of study up to 262 weeks
|
Spasticity improvement for lower body muscle groups based on MAS from study Baseline. The MAS is used to measure the resistance to passive movement about a joint due to spasticity using a 6-point scoring scale with possible values of 0, 1, 1+ (scored as 1.5), 2, 3, and 4, where 0 is no increase in muscle tone (no spasticity) and 4 is affected part(s) rigid in flexion or extension (total rigidity). Thus, a decrease in MAS score indicates improvement in spasticity. |
From start of study up to 262 weeks
|
|
Berg Balance Scale (BBS)
Prazo: From start of study up to 262 weeks
|
Change from study Baseline. The BBS, a measure of balance, utilizes a 5-point scoring scale of 0 (indicating the lowest level of function) to 4 (indicating the highest level of function) for 14 tasks, giving a scale range of 0-56, with a higher score representing better balance. |
From start of study up to 262 weeks
|
|
Purdue Pegboard Test (Dominant Hand)
Prazo: From start of study up to 262 weeks
|
Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average. |
From start of study up to 262 weeks
|
|
Purdue Pegboard Test (Non-dominant Hand)
Prazo: From start of study up to 262 weeks
|
Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average. |
From start of study up to 262 weeks
|
|
Number of Participants With Hyperammonemic Episodes
Prazo: From study start up to 262 weeks
|
Hyperammonemic episodes" are defined as either an AE for which an Investigator observed symptoms considered to be consistent with a "hyperammonemic episode", or an AE in a patient meeting all 3 of the following criteria: 1. Confirmed ammonia level ≥100 μM, 2. One or more symptoms related to hyperammonemia, 3. Requiring hospitalization or emergency room management. |
From study start up to 262 weeks
|
|
Number of Participants With Seizures
Prazo: From study start up to 262 weeks
|
From study start up to 262 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Diretor de estudo: Mattias Rudebeck, PhD MSc BMedSc, Immedica Pharma AB
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Metabolismo, Erros Inatos
- Doenças Genéticas, Congênitas
- Doenças Metabólicas
- Doenças Cerebrais Metabólicas Inatas
- Doenças Cerebrais Metabólicas
- Metabolismo de Aminoácidos, Erros Inatos
- Distúrbios Inatos do Ciclo da Uréia
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças Nutricionais e Metabólicas
- Hiperargininemia
Outros números de identificação do estudo
Outros números de identificação do estudo
- CAEB1102-102A
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .